Paratek Pharmaceuticals (PRTK) Shareholder Roumell Asset Management Cut Its Position as Share Value Rose; Mesirow Financial Investment Management Us Value Equity Upped Its Position in Virtusa (VRTU) by $6.94 Million

February 16, 2018 - By Dolores Ford

Jim Roumell decreased its stake in Paratek Pharmaceuticals Inc (PRTK) by 60.66% based on its latest 2017Q3 regulatory filing with the SEC. Roumell Asset Management Llc sold 156,349 shares as the company’s stock rose 33.85% with the market. The hedge fund run by Jim Roumell held 101,399 shares of the health care company at the end of 2017Q3, valued at $2.55M, down from 257,748 at the end of the previous reported quarter. Roumell Asset Management Llc who had been investing in Paratek Pharmaceuticals Inc for a number of months, seems to be less bullish one the $432.25 million market cap company. The stock decreased 0.36% or $0.05 during the last trading session, reaching $13.9. About 56,935 shares traded. Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has risen 62.03% since February 16, 2017 and is uptrending. It has outperformed by 45.33% the S&P500.

Mesirow Financial Investment Management Us Value Equity increased its stake in Virtusa Corp (VRTU) by 79.97% based on its latest 2017Q3 regulatory filing with the SEC. Mesirow Financial Investment Management Us Value Equity bought 187,675 shares as the company’s stock declined 1.05% while stock markets rallied. The institutional investor held 422,359 shares of the edp services company at the end of 2017Q3, valued at $15.96M, up from 234,684 at the end of the previous reported quarter. Mesirow Financial Investment Management Us Value Equity who had been investing in Virtusa Corp for a number of months, seems to be bullish on the $1.46B market cap company. The stock increased 0.08% or $0.04 during the last trading session, reaching $49.53. About 19,690 shares traded. Virtusa Corporation (NASDAQ:VRTU) has declined 13.10% since February 16, 2017 and is downtrending. It has underperformed by 29.80% the S&P500.

Investors sentiment decreased to 1.54 in Q3 2017. Its down 0.35, from 1.89 in 2017Q2. It is negative, as 17 investors sold PRTK shares while 29 reduced holdings. 33 funds opened positions while 38 raised stakes. 20.11 million shares or 4.43% more from 19.26 million shares in 2017Q2 were reported. Fmr Ltd invested in 0% or 1.46 million shares. Davidson Kempner Mngmt LP holds 268,001 shares or 0.2% of its portfolio. Appleton Prtnrs Ma holds 9,109 shares or 0.04% of its portfolio. Perceptive Lc accumulated 21,186 shares. Great West Life Assurance Can accumulated 4,139 shares. State Street invested 0% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Geode Capital Mgmt Ltd Liability Com owns 195,631 shares. Iguana Management, New York-based fund reported 35,000 shares. Tiaa Cref Inv Mgmt Llc invested in 0% or 63,915 shares. Florida-based Raymond James has invested 0% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). 20,619 are owned by Bogle Investment LP De. 26,600 were accumulated by Alliancebernstein Limited Partnership. Omni Llp reported 147,700 shares. Abingworth Llp holds 1.04M shares or 18.09% of its portfolio. 101,399 are owned by Roumell Asset Ltd.

Analysts await Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) to report earnings on March, 1. They expect $-0.72 EPS, up 37.93% or $0.44 from last year’s $-1.16 per share. After $-0.77 actual EPS reported by Paratek Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -6.49% EPS growth.

Roumell Asset Management Llc, which manages about $293.14 million and $42.50 million US Long portfolio, upped its stake in Marchex Inc (NASDAQ:MCHX) by 245,220 shares to 1.44 million shares, valued at $4.45M in 2017Q3, according to the filing. It also increased its holding in Rosetta Stone Inc (NYSE:RST) by 170,622 shares in the quarter, for a total of 767,625 shares, and has risen its stake in Five Point Holdings Llc.

Among 10 analysts covering Paratek Pharmaceuticals (NASDAQ:PRTK), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Paratek Pharmaceuticals had 24 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was initiated by Robert W. Baird on Friday, May 13 with “Outperform”. On Thursday, October 27 the stock rating was reinitiated by Leerink Swann with “Outperform”. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, June 29. On Friday, August 14 the stock rating was upgraded by Zacks to “Sell”. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, July 18 report. The stock of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) earned “Buy” rating by Leerink Swann on Thursday, June 15. On Monday, June 5 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The firm has “Hold” rating by Zacks given on Wednesday, September 2. Zacks upgraded Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) on Tuesday, September 22 to “Hold” rating. The rating was maintained by Wedbush on Tuesday, April 4 with “Outperform”.

Among 10 analysts covering Virtusa (NASDAQ:VRTU), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Virtusa had 32 analyst reports since July 29, 2015 according to SRatingsIntel. Barrington Research maintained it with “Outperform” rating and $67 target in Thursday, November 5 report. Maxim Group maintained the shares of VRTU in report on Wednesday, November 4 with “Buy” rating. The firm has “Buy” rating by Needham given on Thursday, November 10. The stock of Virtusa Corporation (NASDAQ:VRTU) has “Buy” rating given on Friday, October 16 by Cantor Fitzgerald. The stock of Virtusa Corporation (NASDAQ:VRTU) has “Buy” rating given on Wednesday, June 29 by Maxim Group. As per Wednesday, August 10, the company rating was maintained by Cantor Fitzgerald. The rating was maintained by SunTrust with “Buy” on Thursday, February 8. The rating was maintained by Barrington Research with “Outperform” on Tuesday, February 9. The company was maintained on Thursday, November 10 by Maxim Group. The firm has “Buy” rating by Suntrust Robinson given on Friday, February 19.

Mesirow Financial Investment Management Us Value Equity, which manages about $12.10B and $1.52B US Long portfolio, decreased its stake in Littelfuse Inc (NASDAQ:LFUS) by 46,495 shares to 79,688 shares, valued at $15.61M in 2017Q3, according to the filing. It also reduced its holding in Ishares Tr (IVV) by 30,520 shares in the quarter, leaving it with 4,015 shares, and cut its stake in Idacorp Inc (NYSE:IDA).

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>